Objectif Background: To bypass hardware-related complication there have been substantial efforts to create biological pacemakers. Effective strategies have been identified and are now being refined for delivery of long-term function and clinical application. Yet, currently developed biological pacemakers only provide pacing to atrium or ventricle thereby aiming at ~20% of pacemaker patients. To unleash the full potential of biological pacing, targeting virtually every pacemaker patient, effective repair of atrio-ventricular (AV) conduction is crucial. With the arrival of advanced stem cell-based therapies, now is the time to meet this important challenge. Objective: To develop a stem cell-based therapy that restores impulse formation and conduction at the interface between atrium and ventricle.Approach: Human induced pluripotent stem cells (hiPSCs) will be used to produce cells with hallmark features of AV nodal cells. After in vitro testing, these cells will be implanted in vivo (together with biomaterials) to form AV bypass tracts in sheep that are in permanent AV block. In this setting, approaches will be tested for their ability to bridge electrical activity from the atrium to ventricle and protect the ventricle from atrial tachycardia. The final steps of this project focuses on the development of dedicated implantation catheters (in collaboration with Medtronic) and optimization of cellular constructs that are regulatory compliant and ready for clinical testing.Impact: By developing novel therapies to re-establish AV impulse formation and conduction I will broaden the application area of biological pacing to nearly all patients. In Europe ~300.000 pacemakers are implanted annually representing cots of ~8 billion Euros. Five per cent of these implantations result in serious complications requiring re-implantation or other invasive treatments. Biological pacemakers are expected to reduce these complications, improve quality of life, and reduce healthcare costs. Champ scientifique medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmiamedical and health sciencesmedical biotechnologycells technologiesstem cellsengineering and technologyindustrial biotechnologybiomaterials Mots‑clés Cardiac arrhythmias Biological pacing AV-node regeneration Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Thème(s) ERC-2016-STG - ERC Starting Grant Appel à propositions ERC-2016-STG Voir d’autres projets de cet appel Régime de financement ERC-STG - Starting Grant Institution d’accueil ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM Contribution nette de l'UE € 1 499 995,00 Adresse MEIBERGDREEF 15 1105AZ Amsterdam Pays-Bas Voir sur la carte Région West-Nederland Noord-Holland Groot-Amsterdam Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 1 499 995,00 Bénéficiaires (1) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM Pays-Bas Contribution nette de l'UE € 1 499 995,00 Adresse MEIBERGDREEF 15 1105AZ Amsterdam Voir sur la carte Région West-Nederland Noord-Holland Groot-Amsterdam Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 1 499 995,00
